RxDoctor Payments DataLook up a doctor →

Abdul Hai Mansoor, MD

Hematology & Oncology · Portland, ORNPI 1790934149

Payments from drug & device makers

$3,500,742in general payments, 2019–2025

Across 409 payments — averaging $8559.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.1M
  • Incyte Corporation$1.1M
  • Genentech, Inc.$603K
  • Karyopharm Therapeutics Inc.$153K
  • Regeneron$149K
  • ADC Therapeutics America, Inc.$143K
  • plus $310K from 9 others
$7,192in research payments, 2019–2025

Across 3 payments — averaging $2397.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$829

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,500,742 in reported general payments places this provider in the 90th percentile of 112 hematology & oncology providers in Oregon.

See all hematology & oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$26,971
Medicare patients
12
Services billed
511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide193$2,418,468
PomalystPomalidomide55$1,364,792
BrukinsaZanubrutinib59$777,065
JakafiRuxolitinib Phosphate74$628,017
TasignaNilotinib Hcl23$447,567
CalquenceAcalabrutinib Maleate23$330,764
PromactaEltrombopag Olamine13$135,178
AlvaizEltrombopag Choline25$127,969
VenclextaVenetoclax25$93,597
XareltoRivaroxaban40$26,740
NivestymFilgrastim-Aafi36$24,138
EliquisApixaban21$13,124
GranixTbo-Filgrastim16$9,385
Posaconazole32$6,095
Acyclovir182$4,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$28,900$1,364,79255 claims
Incyte CorporationJakafi$1,071,249$628,01774 claims
NovartisTasigna, Promacta$1,071,338$582,74536 claims
AbbVieVenclexta$113,536$93,59725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 hematology & oncology providers in Oregon.

Other hematology & oncology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →